Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Texas Clinical

Neither a doctor nor a teaching hospital

Research payments

$926,195

106 payments

Through program year 2025, Central Texas Clinical is reported as receiving $926,195 in research payments, across 106 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$9,643	5
2024	Research	$228,447	28
2023	Research	$393,550	42
2022	Research	$294,521	30
2020	Research	$33	1

Breakdown

Who paid Research payments · program years 2020–2025

ViiV Healthcare Company $610,881 74 payments
GlaxoSmithKline, LLC. $315,281 31 payments
Eli Lilly and Company $33 1 payment

Studies the money was for Research payments · program years 2020–2025

A Phase Iib Study Evaluating A Long-Acting Intramuscular Regimen of GS $216,287 37 payments
PH 3 HIV Two-Year Non-Inferiority Compared to Standard of Care Safety/ $188,309 10 payments
A Phase 2B Multicenter, Randomized, Open-Label Study Comparing the Eff $125,530 17 payments
A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $110,445 5 payments
A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority $98,129 13 payments
A Phase Iib, Multicenter, Open-Label, Rollover Study Evaluating the Ef $81,568 6 payments
A Phase 1/2, Observer-Blind, Randomized, Placebo Controlled Multi-Coun $41,819 1 payment
A Phase 3B, Multicenter, Single-Arm, Open-Label Study Evaluating the E $26,588 8 payments
A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority $20,269 1 payment
A Phase 3B, Multicenter, Single-Arm, Open-Label Study Evaluating the E $14,335 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.